Literature DB >> 20179023

Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic.

James D Chalmers1, Mudher Al-Khairalla, Philip M Short, Tom C Fardon, John H Winter.   

Abstract

Clostridium difficile infection (CDI) remains a major healthcare problem associated with antibiotic use in hospitals. Recent years have seen a dramatic increase in the incidence of CDI in the UK and internationally. Lower respiratory tract infections (LRTIs) are the leading indication for antibiotic prescription in hospitals and are therefore a critical battleground in the fight against inappropriate antibiotic use and healthcare-associated infections. This article reviews the evidence for interventions to reduce CDI in hospitalized patients with LRTIs. Reducing prescriptions of cephalosporins and fluoroquinolones in favour of penicillin-based regimens and increased use of tetracyclines have been proposed. Expanding outpatient management of LRTIs and reducing length of hospital stay will limit patient exposure to the healthcare environment in which C. difficile is most easily acquired. Intravenous (iv) broad-spectrum antibiotics are often prescribed when narrower spectrum, oral antimicrobials would be equally effective and, in a proportion of patients, antibiotic therapy is used unnecessarily. Shorter antibiotic regimes may be as effective as prolonged therapy and reduce antibiotic-related complications. Early switch from iv to oral therapy allows simpler antibiotic regimens and facilitates early discharge from hospital. Simple improvements in the management of LRTIs have the potential to reduce the incidence of healthcare-associated infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179023     DOI: 10.1093/jac/dkq038

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  The potential impact of biomarker-guided triage decisions for patients with urinary tract infections.

Authors:  A Litke; R Bossart; K Regez; U Schild; M Guglielmetti; A Conca; P Schäfer; B Reutlinger; B Mueller; W C Albrich
Journal:  Infection       Date:  2013-02-24       Impact factor: 3.553

2.  Health care-associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes.

Authors:  Russell T Attridge; Christopher R Frei; Mary Jo V Pugh; Kenneth A Lawson; Laurajo Ryan; Antonio Anzueto; Mark L Metersky; Marcos I Restrepo; Eric M Mortensen
Journal:  J Crit Care       Date:  2016-08-11       Impact factor: 3.425

3.  Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score.

Authors:  Brandon J Webb; Kristin Dascomb; Edward Stenehjem; Holenarasipur R Vikram; Neera Agrwal; Kenneth Sakata; Kathryn Williams; Bruno Bockorny; Kavitha Bagavathy; Shireen Mirza; Mark Metersky; Nathan C Dean
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.

Authors:  Susana Gordo-Remartínez; María Calderón-Moreno; Juan Fernández-Herranz; Ana Castuera-Gil; Mar Gallego-Alonso-Colmenares; Carolina Puertas-López; José A Nuevo-González; Domingo Sánchez-Sendín; Mercedes García-Gámiz; José A Sevillano-Fernández; Luis A Álvarez-Sala; Juan A Andueza-Lillo; José M de Miguel-Yanes
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

5.  External validation of the CURSI criteria (confusion, urea, respiratory rate and shock index) in adults hospitalised for community-acquired pneumonia.

Authors:  Harald Nüllmann; Marc Andre Pflug; Thomas Wesemann; Hans-Jürgen Heppner; Ludger Pientka; Ulrich Thiem
Journal:  BMC Infect Dis       Date:  2014-01-22       Impact factor: 3.090

Review 6.  Pneumonia in low and middle income countries: progress and challenges.

Authors:  H J Zar; S A Madhi; S J Aston; S B Gordon
Journal:  Thorax       Date:  2013-08-16       Impact factor: 9.139

7.  Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD--the ABACOPD study.

Authors:  Gernot G U Rohde; Armin Koch; Tobias Welte
Journal:  BMC Pulm Med       Date:  2015-01-27       Impact factor: 3.317

8.  Procalcitonin, pyuria and proadrenomedullin in the management of urinary tract infections--'triple p in uti': study protocol for a randomized controlled trial.

Authors:  Daniel Drozdov; Anja Thomer; Marc Meili; Stefanie Schwarz; Rita Bossart Kouegbe; Katharina Regez; Merih Guglielmetti; Ursula Schild; Antoinette Conca; Petra Schäfer; Barbara Reutlinger; Cornelia Ottiger; Florian Buchkremer; Alexander Litke; Philipp Schuetz; Andreas Huber; Ulrich Bürgi; Christoph A Fux; Andreas Bock; Beat Müller; Werner C Albrich
Journal:  Trials       Date:  2013-03-22       Impact factor: 2.279

9.  Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial.

Authors:  Jose Vazquez; Annette C Reboli; Peter G Pappas; Thomas F Patterson; John Reinhardt; Peter Chin-Hong; Ellis Tobin; Daniel H Kett; Pinaki Biswas; Robert Swanson
Journal:  BMC Infect Dis       Date:  2014-02-21       Impact factor: 3.090

10.  Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial.

Authors:  Werner C Albrich; Kristina Rüegger; Frank Dusemund; Philipp Schuetz; Birsen Arici; Alexander Litke; Claudine A Blum; Rita Bossart; Katharina Regez; Ursula Schild; Merih Guglielmetti; Antoinette Conca; Petra Schäfer; Maria Schubert; Sabina de Geest; Barbara Reutlinger; Sarosh Irani; Ulrich Bürgi; Andreas Huber; Beat Müller
Journal:  Eur Respir J       Date:  2013-01-24       Impact factor: 16.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.